Photo courtesy of Cummings Properties

A Cambridge biotech is moving from a shared lab space in that city to a dedicated Woburn office following the signing of a lease.

Rgenta Theraputics will take 5,400 square feet in Cummings Properties’ TradeCenter 128, moving on from rented space in the LabCentral incubator space.

Rgenta is developing oral treatments for historically incurable diseases. Its team of small-molecule drug developers is currently focused on pioneering new medicines for cancers and neurological disorders. The venture capital-backed firm announced its receipt of $20 million in seed funding from multiple investors in April of 2020.

“Because our science has such wide applicability, our operation is rapidly expanding,” Rgenta CEO and co-founder Simon Xi said in a statement. “Having outgrown our shared space in Cambridge, we were determined to find a convenient, high-value location that would support our continued evolution.”

Cummings Properties account manager Eric Lawless worked with Newmark director Catie Tilton on the lease, which included a custom lab and office buildout.

“With the current scarcity of available lab space in greater Boston, biotech firms are finding it advantageous to lease from a property manager with in-house design and construction teams,” said Lawless. “Cummings’ ability to efficiently deliver a high-quality, cost-effective lab facility within an established life science hub was a big draw for Rgenta.”

Rgenta’s space is a Biosafety Level 2 facility and features a newly constructed cell-culture room, specialty gas distribution, and an expansive window line as well as new benchwork, fume hoods, and HVAC. Floor-to-ceiling glass partitions separate its offices from its laboratory, allowing staff to enjoy views from the upper-floor office.